ArticleBMC cancer2025
Global, regional, and national burdens of early onset gastric cancer aged 15-49 years from 1990 to 2021 with projections to 2035: a population-based study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Circulating miRNA-30a is associated with favorable therapeutic outcome in patients with gastric cancer treated with neoadjuvant chemotherapy.Oncology letters · 2026Article
- Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010-2023.Hepatology international · 2026Article
- Burden and Forecast of Early-Onset Colorectal Cancer (1990-2038) in Five East Asian Populations: A Systematic Analysis Based on the GBD 2023 Study.Cancer medicine · 2026Article
- Listening to the Past, Shaping the Future: A Data-mining Based and Visual Analysis of Five Decades of Gastric Carcinogenesis Research.Biological procedures online · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly-onset gastric cancer (EOGC) is a distinct clinical entity with unique epidemiological and pathological features. Despite an overall decline in GC incidence in many regions, recent studies have shown an increasing trend in EOGC incidence in some areas. This study aims to systematically evaluate the global, regional, and national burden of EOGC from 1990 to 2021 using data from the Global Burden of Disease (GBD) 2021 study.
methodsData on the incidence, mortality, and disability-adjusted life-years (DALYs) of EOGC were obtained from the GBD 2021 database. The age-standardized incidence rates (ASIRs), age-standardized mortality rates (ASMRs), and age-standardized DALYs rates (ASDRs) were calculated. Estimated annual percentage change (EAPC) was used to assess temporal trends. The Bayesian age-period-cohort model was employed to project trends up to 2035.
resultsGlobally, the ASIR of EOGC decreased from 5.40 per 100,000 in 1990 to 3.17 per 100,000 in 2021 (EAPC -1.8, 95% CI: -1.9 to -1.7). The ASMR decreased from 2.00 per 100,000 in 1990 to 1.31 per 100,000 in 2021 (EAPC -2.4, 95% CI: -2.5 to -2.3), and the ASDR decreased from 97.73 per 100,000 in 1990 to 63.98 per 100,000 in 2021 (EAPC -2.5, 95% CI:-2.6 to -2.4). East Asia had the highest ASIR, ASMR, and ASDR. Regions with higher Socio-demographic Index (SDI) values experienced more significant declines in EOGC incidence and mortality. High-sodium diets and smoking were identified as significant risk factors. Forecasts toward 2035 indicate a continued decline in ASIR, ASMR, and ASDR globally.
conclusionsDespite a decrease in ASIR, ASMR, and ASDR globally, the absolute burden of EOGC remains high, with significant regional disparities. Targeted prevention and treatment strategies are needed, particularly in low- and middle-income countries. Future research should focus on identifying additional risk factors and exploring the effectiveness of different preventive strategies in various regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.